Perspective Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Perspective Therapeutics
CATX Stock   2.81  0.06  2.09%   
Perspective Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Perspective Therapeutics' valuation are provided below:
Gross Profit
-60.9 M
Market Capitalization
208.9 M
Enterprise Value Revenue
68.7327
Revenue
1.1 M
Earnings Share
(1.51)
We have found one hundred twenty available trending fundamental ratios for Perspective Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Perspective Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 469.3 M in 2026. Enterprise Value is likely to rise to about 455.8 M in 2026

Perspective Therapeutics Total Revenue

0.0

Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Total Revenue of 0.0 or Gross Profit of 1.2 M, as well as many indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0 or PTB Ratio of 0.6. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Perspective Stock
Check out the analysis of Perspective Therapeutics Correlation against competitors.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Perspective Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets411.9 M392.3 M88.5 M
Slightly volatile
Short and Long Term Debt Total4.9 M4.7 M1.7 M
Slightly volatile
Total Current Liabilities22 M21 M5.6 M
Slightly volatile
Total Stockholder Equity351 M334.3 M75.5 M
Slightly volatile
Property Plant And Equipment Net71.9 M68.5 M13.5 M
Slightly volatile
Current Deferred Revenue1.7 M1.6 M1.4 M
Slightly volatile
Accounts Payable12.5 M11.9 M2.9 M
Slightly volatile
Cash74.4 M70.8 M20.4 M
Slightly volatile
Non Current Assets Total132.8 M126.4 M29.3 M
Slightly volatile
Cash And Short Term Investments274 M261 M55.9 M
Slightly volatile
Net Receivables126.7 K133.4 K943.9 K
Very volatile
Common Stock Shares Outstanding77.8 M74.1 M48.6 M
Slightly volatile
Liabilities And Stockholders Equity411.9 M392.3 M88.5 M
Slightly volatile
Non Current Liabilities Total38.9 M37 M7.5 M
Slightly volatile
Inventory1.7 M1.6 M814.8 K
Slightly volatile
Other Current Assets5 M4.7 M1.7 M
Slightly volatile
Other Stockholder Equity241.7 M470.1 M151 M
Slightly volatile
Total Liabilities60.9 M58 M13 M
Slightly volatile
Total Current Assets279.1 M265.8 M59 M
Slightly volatile
Short Term Debt1.2 M1.2 M383.5 K
Slightly volatile
Common Stock102.2 K63 K79.1 K
Slightly volatile
Intangible Assets60.4 M57.5 M13 M
Slightly volatile
Net Invested Capital353 M336.2 M78.8 M
Slightly volatile
Capital Stock137.5 K80.5 K106.4 K
Slightly volatile
Net Working Capital257.1 M244.9 M52.9 M
Slightly volatile
Capital Lease Obligations2.9 M2.7 M1.2 M
Slightly volatile
Property Plant And Equipment Gross75.5 M71.9 M16.4 M
Slightly volatile
Other Liabilities717.6 K736 K648.2 K
Slightly volatile
Net Tangible Assets49.1 M70.3 M28.7 M
Slightly volatile
Property Plant Equipment2.1 M2.2 M2.6 M
Slightly volatile
Long Term Debt1.3 M1.5 M1.6 M
Slightly volatile
Short and Long Term Debt55.5 K59.8 K50.2 K
Slightly volatile
Non Current Liabilities Other44 K49.5 K54 K
Slightly volatile

Perspective Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses51.2 M48.7 M19.8 M
Slightly volatile
Cost Of Revenue4.1 M4.9 M4.8 M
Pretty Stable
Total Operating Expenses111.5 M106.2 M26.4 M
Slightly volatile
Interest Expense41 K43.2 K64.6 K
Pretty Stable
Selling General Administrative32.1 M30.6 M9.6 M
Slightly volatile
Selling And Marketing Expenses106 K111.5 K1.5 M
Very volatile
Research Development50.3 M47.9 M10.3 M
Slightly volatile
Net Interest Income12.6 M12 M2.2 M
Slightly volatile
Interest Income12.7 M12.1 M2.3 M
Slightly volatile
Reconciled Depreciation2.8 M2.7 M670.7 K
Slightly volatile

Perspective Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow8 M10.8 M12.5 M
Slightly volatile
Depreciation2.8 M2.7 M841 K
Slightly volatile
Capital Expenditures65.7 M62.6 M11 M
Slightly volatile
End Period Cash Flow74.4 M70.8 M25.7 M
Slightly volatile
Stock Based Compensation6.5 M6.2 M1.6 M
Slightly volatile
Change To Operating Activities169.8 K209.3 K177.5 K
Very volatile
Change To Netincome702.9 K1.3 M646 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio140177177
Slightly volatile
Dividend Yield0.00.00.0
Pretty Stable
PTB Ratio0.60.6427.0605
Slightly volatile
Days Sales Outstanding283269121
Slightly volatile
Book Value Per Share4.264.061.2165
Slightly volatile
Average Payables219.2 K230.7 K274.7 K
Slightly volatile
Stock Based Compensation To Revenue2.462.350.642
Slightly volatile
Capex To Depreciation28.4927.146.4016
Slightly volatile
PB Ratio0.60.6427.0605
Slightly volatile
EV To Sales131172165
Slightly volatile
Inventory Turnover4.244.468.8303
Slightly volatile
Days Of Inventory On Hand88.8584.6253.9238
Slightly volatile
Payables Turnover3.884.086.1085
Slightly volatile
Sales General And Administrative To Revenue13.8213.163.9262
Slightly volatile
Average Inventory19.6 K20.6 K133.9 K
Slightly volatile
Research And Ddevelopement To Revenue14.0413.383.5337
Slightly volatile
Capex To Revenue0.90.860.4339
Pretty Stable
Cash Per Share3.333.171.1459
Pretty Stable
Days Payables Outstanding112118377
Slightly volatile
Income Quality0.20.210.7406
Slightly volatile
Intangibles To Total Assets0.110.170.0828
Slightly volatile
Current Ratio11.9811.4110.6227
Pretty Stable
Tangible Book Value Per Share3.533.361.0044
Slightly volatile
Receivables Turnover1.331.44.4624
Slightly volatile
Shareholders Equity Per Share4.264.061.2165
Slightly volatile
Debt To Equity0.01530.01610.1348
Slightly volatile
Capex Per Share1.020.970.179
Slightly volatile
Average Receivables50.4 K53.1 K370.3 K
Slightly volatile
Revenue Per Share0.02850.030.0988
Slightly volatile
Interest Debt Per Share0.06810.07170.0247
Slightly volatile
Debt To Assets0.0130.01370.086
Slightly volatile
Operating Cycle283269154
Slightly volatile
Price Book Value Ratio0.60.6427.0605
Slightly volatile
Days Of Payables Outstanding112118377
Slightly volatile
Company Equity Multiplier0.841.061.2887
Slightly volatile
Long Term Debt To Capitalization0.00610.00640.0276
Slightly volatile
Total Debt To Capitalization0.01510.01580.1101
Slightly volatile
Debt Equity Ratio0.01530.01610.1348
Slightly volatile
Quick Ratio11.9811.4110.3143
Slightly volatile
Net Income Per E B T1.061.120.9946
Slightly volatile
Cash Ratio3.173.045.9401
Pretty Stable
Days Of Inventory Outstanding88.8584.6253.9238
Slightly volatile
Days Of Sales Outstanding283269121
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio3.763.581.5466
Slightly volatile
Price To Book Ratio0.60.6427.0605
Slightly volatile
Fixed Asset Turnover0.250.263.2811
Slightly volatile
Debt Ratio0.0130.01370.086
Slightly volatile
Price Sales Ratio140177177
Slightly volatile
Asset Turnover0.0160.01680.3536
Slightly volatile
Price Fair Value0.60.6427.0605
Slightly volatile

Perspective Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap469.3 M253.8 M351.4 M
Slightly volatile
Enterprise Value455.8 M246.1 M324.6 M
Slightly volatile

Perspective Fundamental Market Drivers

Perspective Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Perspective Therapeutics Financial Statements

Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.6 M1.7 M
Cost Of Revenue4.9 M4.1 M
Stock Based Compensation To Revenue 2.35  2.46 
Sales General And Administrative To Revenue 13.16  13.82 
Research And Ddevelopement To Revenue 13.38  14.04 
Capex To Revenue 0.86  0.90 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(32.83)(31.19)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY